Travere Therapeutics (TVTX) Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
September 30, 2024 6:13 AM EDTBarclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More
Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
September 27, 2024 7:23 AM EDTCiti analyst Carly Kenselaar lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $19.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "The enrollment pause in the Ph3 HCU trial triggered by the pegtibatinase manufacturing scale-up not meeting required specs is obviously... More
